Difference between revisions of "Section 3.2.4: NF-kappaB signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8472)"
Jump to navigation
Jump to search
(Created claim: Has Sectioning (P146): Section 4.1: Agents targeting CSC-associated surface biomarkers in clinical trials (from DOI: 10.1038/s41392-020-0110-5) (Q8487), #quickstatements; #temporary_batch_1589931845914) |
(Created claim: Has Sectioning (P146): Section 4.2: Agents targeting CSC-associated signaling pathways in clinical trials (from DOI: 10.1038/s41392-020-0110-5) (Q8488), #quickstatements; #temporary_batch_1589931845914) |
||
| Property / Has Sectioning | |||
| + | |||
| Property / Has Sectioning: Section 4.2: Agents targeting CSC-associated signaling pathways in clinical trials (from DOI: 10.1038/s41392-020-0110-5) / rank | |||
| + | Normal rank | ||
Revision as of 23:48, 19 May 2020
Publication: "Targeting cancer stem cell pathways for cancer therapy" published as Signal Transduct Target Ther; 2020 ; 5 8; DOI: 10.1038/s41392-020-0110-5
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Section 3.2.4: NF-kappaB signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)
|
Publication: "Targeting cancer stem cell pathways for cancer therapy" published as Signal Transduct Target Ther; 2020 ; 5 8; DOI: 10.1038/s41392-020-0110-5
|
Statements
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
